{"id":474171,"date":"2021-04-09T08:18:03","date_gmt":"2021-04-09T12:18:03","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=474171"},"modified":"2021-04-09T08:18:03","modified_gmt":"2021-04-09T12:18:03","slug":"mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\/","title":{"rendered":"Mersana Therapeutics to Host Conference Call and Webcast to Discuss the Selection of the NaPi2b Biomarker Cutoff and Commercial Diagnostic Development Path"},"content":{"rendered":"<h2>\nConference Call and webcast to be held on Friday, April 16, 2021, at 8:00 a.m. ET<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">CAMBRIDGE, Mass., April  09, 2021  (GLOBE NEWSWIRE) &#8212; Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced plans to host a conference call and webcast on Friday, April 16, 2021 at 8:00 a.m. ET to discuss the selection of the NaPi2b biomarker cutoff and the commercial diagnostic development path for the ongoing UPLIFT registration strategy in platinum-resistant ovarian cancer. The presentation will review the Company\u2019s plan to deliver a robust, predictive and reproducible commercial diagnostic assay.<\/p>\n<p align=\"justify\">To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 4598737. A live webcast of the presentation will be available on the Investors &amp; Media section of the Mersana website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zmiC24nCNQ6V1pq0UzCefQpCfxC5B2uM5h1PBweruZbNrznqnJYk2MrBA6gM3AVOoJ3wMNfkFwimleBSLJOMdw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.mersana.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Mersana Therapeutics<\/strong><br \/>\n        <br \/>Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana\u2019s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registration strategy, in patients with platinum-resistant ovarian cancer as well as the expansion portion of a Phase 1 proof-of-concept clinical study in patients with NSCLC adenocarcinoma. XMT-1592, Mersana\u2019s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana\u2019s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company\u2019s early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company\u2019s Immunosynthen platform. In addition, multiple partners are using Mersana\u2019s Dolaflexin platform to advance their ADC pipelines.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking\u201d statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on management\u2019s beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning the Company\u2019s business strategy and the design, progression and timing of its clinical trials, the ability of the single-arm UPLIFT cohort to enable registration, and expectations regarding future clinical trial results based on data achieved to date, and the sufficiency of the Company\u2019s cash on hand. Forward-looking statements generally can be identified by terms such as \u201caims,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201ccontemplates,\u201d \u201ccontinues,\u201d \u201ccould,\u201d \u201cdesigned to,\u201d \u201cefforts,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cgoal,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201con track,\u201d \u201copportunity,\u201d \u201cplans,\u201d \u201cpoised for,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredicts,\u201d \u201cprojects,\u201d \u201cpromises to be,\u201d \u201cseeks,\u201d \u201cshould,\u201d \u201cstrategy,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d or similar expressions and the negatives of those terms. Forward-looking statements represent management\u2019s beliefs and assumptions only as of the date of this press release. The Company\u2019s operations involve risks and uncertainties, many of which are outside its control, and any one of which, or combination of which, could materially affect its results of operations and whether the forward-looking statements ultimately prove to be correct. Factors that may materially affect the Company\u2019s results of operations and whether these forward-looking statements prove to be correct include, among other things, that preclinical testing or early clinical results may not be predictive of the results or success of ongoing or later preclinical or clinical studies, that the identification, development and testing of the Company\u2019s product candidates and new platforms will take longer and\/or cost more than planned, and that our clinical studies may not be initiated or completed on schedule, if at all, as well as those listed in the Company\u2019s Annual Report on Form 10-K filed on February 26, 2021, with the Securities and Exchange Commission (\u201cSEC\u201d), and subsequent SEC filings. In addition, while we expect that the COVID-19 pandemic might adversely affect the Company\u2019s preclinical and clinical development efforts, business operations and financial results, the extent of the impact on the Company\u2019s operations and the value of and market for the Company\u2019s common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, physical distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.<\/p>\n<p>\n        <strong>Contact:<\/strong>\n      <\/p>\n<p>Investor &amp; Media Contact<br \/>Sarah Carmody, 617-844-8577<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ojR0Bu6i_8laS57OmMuoA5Z1AGccO4aWykn7xMbC61tkCpZCulDcVO8v6Dm30-EzyrBAQKPRGxFfmXTosDP7JZfJiKD5Y8e9c5XkFyqo_t4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">scarmody@mersana.com<\/a><\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMzk5NSM0MTEyNzMzIzIwODQwMzE=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/facdfd21-d66b-4b90-8fb5-86c6188c567f\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Conference Call and webcast to be held on Friday, April 16, 2021, at 8:00 a.m. ET CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) &#8212; Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced plans to host a conference call and webcast on Friday, April 16, 2021 at 8:00 a.m. ET to discuss the selection of the NaPi2b biomarker cutoff and the commercial diagnostic development path for the ongoing UPLIFT registration strategy in platinum-resistant ovarian cancer. The presentation will review the Company\u2019s plan to deliver a robust, predictive and reproducible commercial diagnostic assay. To access the call, please dial 877-303-9226 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Mersana Therapeutics to Host Conference Call and Webcast to Discuss the Selection of the NaPi2b Biomarker Cutoff and Commercial Diagnostic Development Path&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-474171","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mersana Therapeutics to Host Conference Call and Webcast to Discuss the Selection of the NaPi2b Biomarker Cutoff and Commercial Diagnostic Development Path - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mersana Therapeutics to Host Conference Call and Webcast to Discuss the Selection of the NaPi2b Biomarker Cutoff and Commercial Diagnostic Development Path - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Conference Call and webcast to be held on Friday, April 16, 2021, at 8:00 a.m. ET CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) &#8212; Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced plans to host a conference call and webcast on Friday, April 16, 2021 at 8:00 a.m. ET to discuss the selection of the NaPi2b biomarker cutoff and the commercial diagnostic development path for the ongoing UPLIFT registration strategy in platinum-resistant ovarian cancer. The presentation will review the Company\u2019s plan to deliver a robust, predictive and reproducible commercial diagnostic assay. To access the call, please dial 877-303-9226 &hellip; Continue reading &quot;Mersana Therapeutics to Host Conference Call and Webcast to Discuss the Selection of the NaPi2b Biomarker Cutoff and Commercial Diagnostic Development Path&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-09T12:18:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMzk5NSM0MTEyNzMzIzIwODQwMzE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Mersana Therapeutics to Host Conference Call and Webcast to Discuss the Selection of the NaPi2b Biomarker Cutoff and Commercial Diagnostic Development Path\",\"datePublished\":\"2021-04-09T12:18:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\\\/\"},\"wordCount\":810,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMzk5NSM0MTEyNzMzIzIwODQwMzE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\\\/\",\"name\":\"Mersana Therapeutics to Host Conference Call and Webcast to Discuss the Selection of the NaPi2b Biomarker Cutoff and Commercial Diagnostic Development Path - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMzk5NSM0MTEyNzMzIzIwODQwMzE=\",\"datePublished\":\"2021-04-09T12:18:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMzk5NSM0MTEyNzMzIzIwODQwMzE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMzk5NSM0MTEyNzMzIzIwODQwMzE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mersana Therapeutics to Host Conference Call and Webcast to Discuss the Selection of the NaPi2b Biomarker Cutoff and Commercial Diagnostic Development Path\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mersana Therapeutics to Host Conference Call and Webcast to Discuss the Selection of the NaPi2b Biomarker Cutoff and Commercial Diagnostic Development Path - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\/","og_locale":"en_US","og_type":"article","og_title":"Mersana Therapeutics to Host Conference Call and Webcast to Discuss the Selection of the NaPi2b Biomarker Cutoff and Commercial Diagnostic Development Path - Market Newsdesk","og_description":"Conference Call and webcast to be held on Friday, April 16, 2021, at 8:00 a.m. ET CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) &#8212; Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced plans to host a conference call and webcast on Friday, April 16, 2021 at 8:00 a.m. ET to discuss the selection of the NaPi2b biomarker cutoff and the commercial diagnostic development path for the ongoing UPLIFT registration strategy in platinum-resistant ovarian cancer. The presentation will review the Company\u2019s plan to deliver a robust, predictive and reproducible commercial diagnostic assay. To access the call, please dial 877-303-9226 &hellip; Continue reading \"Mersana Therapeutics to Host Conference Call and Webcast to Discuss the Selection of the NaPi2b Biomarker Cutoff and Commercial Diagnostic Development Path\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-09T12:18:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMzk5NSM0MTEyNzMzIzIwODQwMzE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Mersana Therapeutics to Host Conference Call and Webcast to Discuss the Selection of the NaPi2b Biomarker Cutoff and Commercial Diagnostic Development Path","datePublished":"2021-04-09T12:18:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\/"},"wordCount":810,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMzk5NSM0MTEyNzMzIzIwODQwMzE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\/","name":"Mersana Therapeutics to Host Conference Call and Webcast to Discuss the Selection of the NaPi2b Biomarker Cutoff and Commercial Diagnostic Development Path - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMzk5NSM0MTEyNzMzIzIwODQwMzE=","datePublished":"2021-04-09T12:18:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMzk5NSM0MTEyNzMzIzIwODQwMzE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMzk5NSM0MTEyNzMzIzIwODQwMzE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-napi2b-biomarker-cutoff-and-commercial-diagnostic-development-path\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Mersana Therapeutics to Host Conference Call and Webcast to Discuss the Selection of the NaPi2b Biomarker Cutoff and Commercial Diagnostic Development Path"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/474171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=474171"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/474171\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=474171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=474171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=474171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}